2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow dolasetron: new trials by email Literature Review of dolasetron trials Research Report on dolasetron
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose - Chemotherapy-induced Nausea and Vomiting | Phase 4 | Completed | Helsinn Healthcare SA | 414 | 2021-02-01 | 2025-12-02 |
| A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) Aprepitant, Aprepitant Placebo, Ondansetron - Nausea, Vomiting | Phase 4 | Completed | Merck Sharp & Dohme LLC | 494 | 2012-12-12 | 2018-09-25 |
Vomiting (2) · Nausea (1) · Neoplasms (1)
Helsinn Healthcare SA (1) · Merck Sharp & Dohme LLC (1)
China (1) · Czechia (1) · Germany (1) · Greece (1) · Spain (1) · Switzerland (1) · United Kingdom (1)